Redeye initiates coverage of Nanexa

Report this content

Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. Our confidence in management’s ability to commercialise its technology platform underpins our positive stance, while the share’s undemanding valuation after a recent capital raise provides an attractive entry point.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.